Sidekick Health raises $20m to fund digital therapeutics expansionGamified digital therapeutics firm Sidekick Health has raised $20 million in a Series A funding round, which it Share XSidekick Health raises $20m to fund digital therapeutics expansionhttps://pharmaphorum.com/news/sidekick-health-raises-20m-to-fund-digital-therapeutics-expansion/
Russia’s COVID-19 vaccine filed with WHO, as MHRA reviews Moderna shotRussia’s sovereign wealth fund has filed applications with the World Health Organization (WHO) that if approved could see Share XRussia’s COVID-19 vaccine filed with WHO, as MHRA reviews Moderna shothttps://pharmaphorum.com/market-access-2/russias-sputnik-v-covid-19-shot-filed-with-who/
COVID-19 bites into Pfizer’s Q3, but biopharma revenues risePfizer is one of the front-runners in the race to approve a COVID-19 vaccine but the US company Share XCOVID-19 bites into Pfizer’s Q3, but biopharma revenues risehttps://pharmaphorum.com/news/covid-bites-into-pfizers-q3-but-biopharma-revenues-rise/
Catabasis craters after giving up on muscular dystrophy leadCatabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after Share XCatabasis craters after giving up on muscular dystrophy leadhttps://pharmaphorum.com/news/catabasis-craters-after-giving-up-on-muscular-dystrophy-lead/
WebMD buys German health information company coliquioWebMD Health Corp. is acquiring coliquio, a digital medical information company for German-speaking health professionals. Coliquio is used Share XWebMD buys German health information company coliquiohttps://pharmaphorum.com/news/webmd-buys-german-health-information-company-coliquio/
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trialEli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run Share XNIAID drops Lilly antibody from ACTIV-3 COVID-19 trialhttps://pharmaphorum.com/news/niaid-drops-lilly-antibody-from-activ-3-covid-19-trial/
Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabiliseNovartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new Share XNovartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilisehttps://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/
BioSig abandons COVID-19 drug trial on safety concernsUS biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury Share XBioSig abandons COVID-19 drug trial on safety concernshttps://pharmaphorum.com/news/biosig-abandons-covid-19-drug-trial-on-safety-concerns/
Bayer buys cell & gene therapy firm AskBio for $4 billionBayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US Share XBayer buys cell & gene therapy firm AskBio for $4 billionhttps://pharmaphorum.com/news/bayer-extends-reach-in-cell-gene-therapy-with-askbio-acquisition/
